These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22008654)

  • 21. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
    De Socio GV; Bonfanti P; Ricci E; Orofino G; Madeddu G; Penco G; Gianelli E; Martinelli C; Carradori S; Quirino T; Rizzardini G;
    Biomed Pharmacother; 2008 Jan; 62(1):16-20. PubMed ID: 17851026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy.
    Koyanagi A; Humphrey JH; Ntozini R; Nathoo K; Moulton LH; Iliff P; Mutasa K; Ruff A; Ward B;
    Pediatr Infect Dis J; 2011 Jan; 30(1):45-51. PubMed ID: 21173675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nutritional assessment and lipid profile in HIV-infected children and adolescents treated with highly active antiretroviral therapy.
    Tremeschin MH; Sartorelli DS; Cervi MC; Negrini BV; Salomão RG; Monteiro JP
    Rev Soc Bras Med Trop; 2011; 44(3):274-81. PubMed ID: 21739071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials.
    Rojas C; Coplan PM; Rhodes T; Robertson MN; DiNubile MJ; Guess HA
    Pharmacoepidemiol Drug Saf; 2003; 12(5):361-9. PubMed ID: 12899109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of adiponectin-encoding gene ADIPOQ single nucleotide polymorphisms +45 and +276 on serum lipid levels after antiretroviral therapy in Japanese patients with HIV-1-infection.
    Kato H; Ohata A; Samukawa S; Ueda A; Ishigatsubo Y
    J Int Med Res; 2016 Apr; 44(2):297-306. PubMed ID: 26831403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Myocardial infarction in the course of antiretroviral therapy with protease inhibitor].
    Buccoliero G; Lonero G; Rollo MA; Cristiano L; Romanelli C; Loperfido P; Chimienti A; Angelini P; Resta F
    Recenti Prog Med; 2003 Jun; 94(6):264-6. PubMed ID: 12793098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
    Hirsch HH; Battegay M
    Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():42-3. PubMed ID: 19024917
    [No Abstract]   [Full Text] [Related]  

  • 31. Dyslipidaemia and insulin resistance in vertically HIV-infected children and adolescents.
    dos Reis LC; de Carvalho Rondó PH; de Sousa Marques HH; de Andrade SB
    Trans R Soc Trop Med Hyg; 2011 Apr; 105(4):197-203. PubMed ID: 21371728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study.
    Kim JY; Zaoutis T; Chu J; Zhao H; Rutstein R
    Pharmacoepidemiol Drug Saf; 2009 Jul; 18(7):589-94. PubMed ID: 19402031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperlipidemia in HIV-positive patients receiving antiretrovirals.
    Segarra-Newnham M
    Ann Pharmacother; 2002 Apr; 36(4):592-5. PubMed ID: 11918504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
    Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
    AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lipodystrophy in HIV infected children].
    Popielska J
    Pol Merkur Lekarski; 2008 May; 24(143):408-13. PubMed ID: 18634383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy.
    Charakida M; Loukogeorgakis SP; Okorie MI; Masi S; Halcox JP; Deanfield JE; Klein NJ
    Antivir Ther; 2009; 14(8):1075-9. PubMed ID: 20032537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
    Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
    HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
    Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
    Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.